Clinical trials: Stroke, Cryptogenic
Paroxysmal Atrial Fibrillation, Cardiac Rhythm Disorder
Atrial Anomalies Predict Silent Atrial Fibrillation Detected by Implantable Cardiac Monitor in Cryptogenic Stroke
Cryptogenic stroke (CS) causes about 30% of admissions to a stroke unit. Silent paroxysmal atrial fibrillation (PAF) is believed to be the underlying cause of a significant proportion of patients.
- Conditions
- Paroxysmal Atrial Fibrillation, Cardiac Rhythm Disorder, Left Atrial Dilatation, Cryptogenic Stroke
- Trial name
- CRIPTO-FAST (NCT06542770)
- Testing
- Early implant of cardiac monitor
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Parc de Salut Mar
Ischemic Stroke, Cryptogenic, Ischemic Stroke, Embolic
Left Atrial Strain and Cryptogenic Stroke
Cryptogenic stroke is a type of stroke in which the cause of the blood clot cannot be identified, leaving many patients without a clear treatment plan and at high risk for another stroke.
- Conditions
- Ischemic Stroke, Cryptogenic, Ischemic Stroke, Embolic, Hemorrhagic Stroke, Embolic Stroke of Undetermined Source
- Trial name
- LAS-ESUS (NCT07224178)
- Where
- United States
- Volunteers
- 900 people
- Sponsor
- University of Pittsburgh
Patent Foramen Ovale, Stroke
Comparing Two PFO Closure Devices in Adults With Previous Stroke or TIA
This study is a prospective, multicenter, randomized, controlled, single-blind, investigator-driven, non-profit clinical trial designed to compare the safety and efficacy of the Cocoon PFO Occluder with the Amplatzer PFO Occluder…
- Conditions
- Patent Foramen Ovale, Stroke, Transient Ischemic Attack (TIA)
- Trial name
- SAFE-PFO (NCT07380490)
- Testing
- PFO Closure procedure
- Where
- Germany
- Volunteers
- 1,260 people
- Sponsor
- Giuseppe Tarantini
Cryptogenic Stroke, Atrial Fibrillation
Improving AF Detection in Cryptogenic Stroke
No cause for stroke is found in up to 30% of cases despite extensive investigations. These are called cryptogenic strokes (CS). 1 in 4 stroke survivors will suffer another in 5 years and this is a leading cause of fear and…
- Trial name
- CSAF-AW (NCT05007847)
- Testing
- Apple Watch-based heart rhythm monitoring
- Where
- 4 sites in United Kingdom
- Volunteers
- 27 people
- Sponsor
- Barts & The London NHS Trust
Stroke
Finding Atrial Fibrillation in Patients With Unexplained Stroke Using Longterm Cardiac Monitoring
The SURPRISE study investigates atrial fibrillation(AFIB) in patients with a previous unexplained stroke. It uses long term monitoring of the heart of up to three years, searching for paroxysmal atrial fibrillation(PAF) otherwise…
- Trial name
- SURPRISE (NCT01498146)
- Where
- Denmark
- Volunteers
- 85 people
- Sponsor
- Bispebjerg Hospital
Atrial Fibrillation, Stroke
Extended Rhythm SCreening for AtRial Fibrillation in Cryptogenic Stroke Patients
Recent studies demonstrated that prolonged rhythm observation increases the detection of atrial fibrillation in patients prior diagnosed as cryptogenic stroke.
- Trial name
- SCARF (NCT01550042)
- Where
- Netherlands
- Volunteers
- 4 people
- Sponsor
- Medisch Spectrum Twente
Atrial Fibrillation, Ischemic Stroke
Mobile Phones in Cryptogenic Stroke Patients Bringing Single Lead ECGs to Detect Atrial Fibrillation
The main objective of this study is to compare the incidence of detected atrial fibrillation (AF) in cryptogenic stroke patients by a single lead ECG device with the incidence of detected AF by a 7-Day Holter ECG.
- Conditions
- Atrial Fibrillation, Ischemic Stroke, Transient Ischemic Attack
- Trial name
- MOBILE-AF (NCT02507986)
- Testing
- Single lead ECG device, 7-Day Holter monitor.
- Where
- 7 sites in Denmark, Netherlands
- Volunteers
- 57 people
- Sponsor
- Leiden University
Cryptogenic Transient Ischemic Attack and Minor Stroke
Predictors of Occult Atrial Fibrillation in 171 Patients With Cryptogenic TIA and Minor Stroke
Retrospective study, single-center, on 171 patients, presented a cryptogenic TIA and Minor stroke. This study objective is to determine profitability of Holter 21 days for screening paroxystic ACFA / flutter in cryptogenic…
- Trial name
- HOLTER-21J (NCT03166969)
- Testing
- Holter 21 days
- Where
- France
- Volunteers
- 171 people
- Sponsor
- Versailles Hospital
Patent Foramen Ovale, Cryptogenic Stroke
Long-term Outcomes After Percutaneous Patent Foramen Ovale Closure (Severance PFO Registry)
Patent foramen ovale (PFO) is a congenital interatrial communication present in about one quarter of the general population and is recognized as a major cause of cryptogenic stroke.
- Conditions
- Patent Foramen Ovale, Cryptogenic Stroke, Transient Ischemic Attack Due to Embolism, Atrial Fibrillation
- Trial name
- NCT07724171
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Yonsei University
Atrial Fibrillation, Ischemic Stroke
Atrial Fibrillation in Cryptogenic Stroke and TIA
Background: Different studies with real-life data and randomized controlled trials have shown a detection rate of paroxysmal atrial fibrillation (AF) of 10-20% in patients with cryptogenic stroke using insertable continuous…
- Conditions
- Atrial Fibrillation, Ischemic Stroke, TIA
- Trial name
- NOR-FIB (NCT02937077)
- Testing
- Medtronic Reveal LINQ
- Where
- 2 sites in Norway
- Volunteers
- 259 people
- Sponsor
- Oslo University Hospital
Cryptogenic Stroke, Atrial Fibrillation
Incidence and Predictors of Recurrent Stroke in Cryptogenic Stroke Patients With Atrial Fibrillation
Brief Summary: This study aimed to investigate the risk and factors that predict recurrent stroke in patients who initially had a stroke with no clear cause (called cryptogenic stroke) and were later found to have atrial…
- Conditions
- Cryptogenic Stroke, Atrial Fibrillation, Recurrent Ischemic Stroke
- Trial name
- NCT07126184
- Testing
- Extended Cardiac Monitoring
- Where
- Pakistan
- Volunteers
- 109 people
- Sponsor
- Nangarhar University
Stroke
Left Atrial Function in Recurrent Stroke of Unknown Cause
Stroke is an important cause of disability and the third leading cause of death. Approximately 30 to 40 % of all strokes are estimated to be cryptogenic (i.e. no cause can be found).
- Trial name
- NCT02968329
- Where
- Belgium
- Volunteers
- 500 people
- Sponsor
- Hasselt University
Stroke
AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke
Objectives Primary: To test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in patients with cryptogenic ischemic stroke and atrial cardiopathy.
- Trial name
- ARCADIA (NCT03192215)
- Testing
- Apixaban, Aspirin
- Where
- 177 sites in United States, Canada
- Volunteers
- 1,015 people
- Sponsor
- Columbia University
Foramen Ovale, Patent
The Paradigm II Trial: PFX Closure System in Subjects With Cryptogenic Stroke, Transient Ischemic Attack, Migraine or Decompression Illness
The primary objective of this study is to demonstrate the safety and efficacy of the PFX Closure System when utilized for patent foramen ovale (PFO) in patients suffering from cryptogenic stroke (undetermined cause of stroke)…
- Trial name
- NCT00196040
- Testing
- PFX Closure System
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- Cierra
Atrial Fibrillation (AF)
CATCH AF - Atrial Fibrillation Detection in Cryptogenic Stroke
Early detection of atrial fibrillation detected after stroke (AFDAS) is crucial for secondary stroke prevention, as initiating direct oral anticoagulants (DOACs) can reduce atrial fibrillation (AF)-related stroke risk by up to…
- Trial name
- CATCH-AF (NCT07899788)
- Testing
- CardioWatch 287-2 Group, Control Group
- Where
- Austria
- Volunteers
- 1,500 people
- Sponsor
- Medical University of Graz
Patent Foramen Ovale, Cryptogenic Stroke
Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders.
To evaluate the performance of Cera™ patent foramen ovale occluders developed by Lifetech Scientific (Shenzhen) Co., LTD;
- Trial name
- NCT05774288
- Testing
- Cera™ patent foramen ovale occluders, Another patent foramen ovale occluders
- Where
- 14 sites in China
- Volunteers
- 244 people
- Sponsor
- Lifetech Scientific (Shenzhen) Co., Ltd.
Cryptogenic Stroke, High Risk Patent Foramen Ovale
Evaluation of Prevalence and Clinical Impact of Atrial Fibrillation in Elderly Patients With Cryptogenic Stroke and High-Risk Patent Foramen Ovale
The purpose of DEFENSE-ELDERLY is to identify the prevalence of AF and evaluate the clinical impact of AF in elderly ESUS patients and no other known sources of stroke besides a high-risk patent foramen ovale, and compare it with…
- Trial name
- DefenseElderly (NCT04285918)
- Testing
- Percutaneous device closure
- Where
- South Korea
- Volunteers
- 300 people
- Sponsor
- Asan Medical Center
Atrial Fibrillation, Stroke
"Cryptogenic Stroke and Atrial Fibrillation Detection Through Implantable Loop Recorder (ILR)"
STUDY TYPE: Prospective, national , multicenter, and observational study. OBJECTIVE: To assess the incidence of AF in patients with cryptogenic stroke who have implanted an AF detection device during a period of 2 years.
- Trial name
- CRYPTONITE (NCT01025947)
- Where
- 2 sites in Spain
- Volunteers
- 100 people
- Sponsor
- University of Valencia
Occult Cancer
Intensive Cancer Screening After Cryptogenic Stroke
The INCOGNITO Pilot Trial is a single centre pilot prospective randomized open-label blinded endpoint (PROBE) trial to assess the feasibility of a full-scale randomized trial to determine whether an occult cancer screening…
- Trial name
- INCOGNITO (NCT05733416)
- Testing
- FDG PET/CT, Usual Care
- Where
- 3 sites in Canada
- Volunteers
- 45 people
- Sponsor
- Ottawa Hospital Research Institute
Brain Infarction, Ischemic Stroke
Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome
BACKGROUND: In industrialized countries a considerable and increasing proportion of strokes occur at younger ages. Stroke at young age causes marked disability at worst and thus long-standing socioeconomic consequences and…
- Conditions
- Brain Infarction, Ischemic Stroke, Thrombosis, Foramen Ovale, Patent
- Trial name
- SECRETO (NCT01934725)
- Where
- 19 sites in Estonia, Finland and 11 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- SECRETO Study Consortium